Evaluating heart health effects of a new HIV treatment in rats.
Official title: STUDIES TO EVALUATE THE CARDIOVASCULAR TOXICITY OF AN HIV TRICOMBO THERAPY (ABC/DTG/3TC) IN SPRAGUE DAWLEY (HSD: SPRAGUE DAWLEY® SD®) RATS (F0 DOSED BY ORAL GAVAGE
Funded at Battelle Centers/pub Hlth Res & Evaluatn · NIH-11216034 · Data updated 2026-11-12
This study is looking at how a certain HIV treatment might affect heart health by testing it on rats, so we can better understand any potential risks for people taking this medication.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Battelle Centers/pub Hlth Res & Evaluatn NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | September 16, 2024 |
| Project end | September 15, 2025 |
| Funding year | 2024 |
| Award (this year) | $2,456,000 |
| NIH project number | 75N96024C00005-0-9999-1 |
| Project ID | NIH-11216034 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are considering or currently using combination antiretroviral therapy.
✕Less likely to help
Patients who are not living with HIV or those who are not receiving antiretroviral therapy may not benefit from this research.
What this research studies
This research investigates the cardiovascular toxicity of a specific HIV treatment regimen (ABC/DTG/3TC) using Sprague Dawley rats. The study aims to understand how this combination therapy affects heart health, particularly looking at changes in heart function and structure. By using animal models, researchers hope to uncover potential risks associated with the treatment that may not be evident in human studies. The findings could provide insights into how HIV therapies impact cardiovascular health over time.
Why it matters
Potential benefit: If successful, this research could lead to safer HIV treatment options that minimize cardiovascular risks for patients.
How similar studies have gone: While there is limited data on the cardiovascular effects of HIV treatments in non-human models, previous studies have shown that understanding these effects is crucial for improving patient outcomes.
Where this research is happening
-
Battelle Centers/pub Hlth Res & Evaluatn
Columbus, United States Active
Researchers
- Principal investigator: Fallacara, Dawn — Battelle Centers/pub Hlth Res & Evaluatn
- Study coordinator: Fallacara, Dawn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.